MAP3K1 and neoplasm: To further confirm the necessity of CD8+ T cell–mediated tumor immunity in Map3k1-modulated tumor growth, we used a CD8 neutralizing antibody to deplete CD8+ T cells in mice (Supplemental Figure 3, A and B).